Pierre Squifflet

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Marion van Mackelenbergh, Sibylle Loibl, Michael Untch et al. · Journal of Clinical Oncology · 2023 · 96 citations

Medicine, Oncology, Breast Oncology +16

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Nehal J. Lakhani, Laura Q.M. Chow, Justin F. Gainor et al. · Seoul National University Open Repository (Seoul National University) · 2021 · 95 citations

Pharmacy, Oncology, Pharmacotherapy +9

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

Pierre Squifflet, Everardo D. Saad, Sibylle Loibl et al. · Journal of Clinical Oncology · 2023 · 55 citations

Medicine, Biostatistics, Oncology +15

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

Hans Wildiers, Christel Fontaine, Peter Vuylsteke et al. · Breast Cancer Research and Treatment · 2010 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

Silvy Laporte, Pierre Squifflet, Noémie Baroux et al. · BMJ Open · 2013 · 48 citations · Full text

Medicine, Oncology, Pharmacology +11